Skip to Content

Join the 'Obinutuzumab' group to help and get support from people like you.

Obinutuzumab News

FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma

Posted 23 Nov 2017 by

South San Francisco, CA – November 16, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The ...

Newer Drug May Prolong Lymphoma Remission

Posted 5 Oct 2017 by

WEDNESDAY, Oct. 4, 2017 – A newer drug may beat the standard treatment when it comes to battling the blood cancer follicular lymphoma, a clinical trial suggests. Follicular lymphoma is one type of non-Hodgkin lymphoma, a group of cancers that arise in white blood cells. The new study found that a drug called obinutuzumab (Gazyva) typically kept the cancer under control longer, versus the ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma

Posted 29 Feb 2016 by

South San Francisco, CA – February 26, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan (rituximab)-containing regimen, or whose ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

2 Drugs Show Promise Against Blood Cancers

Posted 30 May 2015 by

SATURDAY, May 30, 2015 – Two new drugs have shown promise in slowing the march of two incurable blood cancers, researchers report. One drug, ibrutinib, appears to greatly improve standard treatment for patients with recurring chronic-lymphocytic leukemia (CLL), the most common adult leukemia in Western countries. Ibrutinib (Imbruvica) reduced the risk of cancer progression or death by 80 percent ...

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be ...

New Drug Combo Might Help Older, Sicker Patients With Leukemia

Posted 9 Jan 2014 by

THURSDAY, Jan. 9, 2014 – A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests. The research, led by German scientists, included nearly 800 older people (average age 73) who had been diagnosed with chronic lymphocytic leukemia. CLL is a cancer of the blood and bone marrow, the tissue inside bones in which blood cells are created. The study was ...

Ask a Question

Further Information

Related Condition Support Groups

Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma

Related Drug Support Groups


Obinutuzumab Patient Information at